MK-677 vs HGH: A Real Comparison for People Who've Already Done the Reading

You're looking at your options for raising IGF-1 levels and you've narrowed it down to two paths: injectable recombinant human growth hormone (rhGH) or MK-677, the oral growth hormone secretagogue. Both move the same needle. The cost differential runs to thousands of dollars per year. The risk profiles are not the same. Here's what the comparison actually looks like when you get past the supplement-stack forums.

What Each One Actually Does

HGH (somatropin) is exogenous recombinant growth hormone — you inject it, it circulates, it raises IGF-1. The FDA has approved it under several brand names (Norditropin, Genotropin, Humatrope) for specific indications including adult growth hormone deficiency. In a clinical context, typical prescribed doses for adults with confirmed deficiency start around 0.2–0.4 mg/day subcutaneously and are titrated upward based on IGF-1 response and side effect tolerance.

MK-677 (ibutamoren) is an orally active ghrelin receptor agonist. It stimulates the pituitary to release more endogenous GH — it does not introduce exogenous hormone. In Svensson et al. (1998), published in Journal of Clinical Endocrinology & Metabolism, 25 mg/day in healthy older adults produced mean IGF-1 increases of roughly 40% from baseline over 12 months. The pituitary still controls pulse architecture; the drug amplifies the signal, it doesn't replace it.

That distinction matters for how both compounds behave inside your body over time.

The IGF-1 Ceiling Problem

With rhGH, your IGF-1 response is largely dose-dependent. You push in more hormone, IGF-1 climbs. The ceiling is essentially your dose — and your physician's willingness to increase it. With MK-677, you're working through a gland that has its own regulatory capacity. Published data and clinical experience converge on 25 mg/day as the effective ceiling for oral MK-677 in healthy adults — going higher doesn't proportionally raise IGF-1 further, and side effects (water retention, elevated fasting glucose, increased appetite) scale with dose more than benefits do.

For people whose goal is genuine deficiency correction rather than optimization above range, rhGH may be more predictable. For people in the optimization window — IGF-1 in the low-normal range, trying to move it toward mid-to-upper normal — MK-677 at 25 mg/day can often accomplish that without injections or a controlled substance prescription.

The Cost Gap Is Not Subtle

Pharmaceutical-grade somatropin prescribed through a US clinic runs $400–$1,200 per month depending on dose, brand, and whether insurance covers any portion. Most anti-aging and longevity applications don't qualify for insurance coverage, so $600–$800/month is a realistic out-of-pocket estimate for a 0.3–0.5 mg/day protocol through a telehealth provider in 2026.

MK-677 sourced through a licensed US compounding pharmacy or peptide clinic typically runs $80–$150/month for 25 mg/day. Over six months, the difference between the two protocols ranges from $2,700 to $6,300.

That cost differential is part of why online hormone programs have leaned toward secretagogue-based protocols for optimization clients who don't qualify for a deficiency diagnosis. It's also why a number of hormone optimization clinics now offer MK-677 alongside peptides like ipamorelin and tesamorelin as part of tiered protocols — lower-cost secretagogues first, injectable GH only when clinically indicated or when secretagogue response is insufficient.

The Regulatory and Safety Distinction

RhGH is Schedule III in several states and a controlled substance federally under some interpretations of athletic doping rules — prescribing it for anti-aging or body composition purposes occupies a gray zone in the US, which is why many physicians won't write the script without solid lab documentation of deficiency (IGF-1 below roughly 100 ng/mL for adults, though reference ranges vary by assay and age bracket).

MK-677 is not a controlled substance in the US as of mid-2026, but it is not FDA-approved for any indication. It's sold as a research chemical in some channels and compounded in others. The 2024 FDA crackdown on certain peptides and research chemicals narrowed availability through grey-market vendors — though compounding pharmacies operating under 503A/503B frameworks have largely maintained access through physician prescriptions.

The side effect profiles differ in character, not just severity. RhGH can suppress endogenous GH production if used long-term at supraphysiologic doses — the pituitary adapts downward. MK-677 doesn't carry that risk because it works through stimulation, not replacement. It does, however, raise fasting glucose in a clinically relevant proportion of users — Svensson et al. documented increases of 0.3–0.6 mmol/L in fasting blood glucose at 25 mg/day — which makes it a poor choice for anyone with borderline insulin sensitivity or a family history of type 2 diabetes without active monitoring.

Which One Belongs in Your Protocol

If your IGF-1 is below range and you have documentation, rhGH is probably the right tool — the dose-response is better understood, and the FDA label gives you and your physician a standard framework. If your IGF-1 is low-normal and your goal is optimization without injection, MK-677 is the rational first-line option given the cost and the absence of exogenous hormone.

A subset of people — particularly those who want the full-spectrum GH pulse profile that MK-677 can't replicate — end up on low-dose rhGH (0.2 mg/day) with MK-677 used intermittently. This stacked approach is common enough that several platforms have formalized it. System Labs is one example that offers tiered GH protocols ranging from peptide-only to injectable GH depending on lab results and patient goals.

The Bottom Line

MK-677 wins on accessibility and cost if your goal is modest IGF-1 elevation — the 40% mean increase documented in Svensson et al. — and you have a functioning pituitary. RhGH wins on precision if you need reliable deficiency correction or are targeting IGF-1 levels that secretagogues can't reach. Anyone comparing these two without labs is making the decision backwards — get an IGF-1 and fasting glucose baseline first, then choose the tool that matches what the numbers actually show. If you want to find a hormone clinic that can order and interpret those labs, that's the actual first step.

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---